Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fezagepras in Alström Syndrome
NCT02739217Phase 2Completed
- Sponsor
- Liminal BioSciences Inc.
- Start
- Feb 2016
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fezagepras in Alström syndrome (ALMS), sponsored by Liminal BioSciences Inc. Primary endpoint: Description and number of abnormal laboratory values and adverse events that are related to treatment. Started Feb 2016; status: completed.
02
Drugs
fezagepras
03
Conditions
Alström syndrome (ALMS)
Beyond the preview
Go deeper on NCT02739217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02739217.